Choroidal neovascularization (CNV) can arise secondary to the retinochoroiditis and macular scarring from ocular toxoplasmosis.1,2 Treatment of CNV due to toxoplasmosis can include corticosteroids, cryotherapy, laser photocoagulation, submacular surgery, and verteporfin photodynamic therapy (PDT).1- 4 We describe 2 cases of CNV secondary to toxoplasmosis treated successfully with PDT.
Case 1. A 20-year-old man with a diagnosis of congenital ocular toxoplasmosis with bilateral macular scars sought care because of a 9-month history of decreasing vision and metamorphopsia in the right eye. Visual acuity was 1/200 OD. Fundus examination results revealed a subfoveal chorioretinal scar with surrounding subretinal hemorrhage and exudate (Figure 1A). Fluorescein angiographic images identified central leakage from the CNV with surrounding blocked fluorescence corresponding to the hemorrhage (Figure 1B and C), while indocyanine green angiographic images were able to provide visualization through the hemorrhage. The eye was treated with PDT and the greatest linear dimension of the treatment spot included all of the hemorrhage.
A, Baseline fundus photographs (OD, OS) show a macular scar with adjacent subretinal fluid, hemorrhage, and exudates in the right eye and a macular scar in the left eye. B and C, Baseline early- and late-phase fluorescein angiographic images showing leakage from choroidal neovascularization and hypofluorescence corresponding to hemorrhage. D, Posttreatment fundus photographs taken at 10 months showing a macular scar with no evidence of subretinal fluid, hemorrhage, or exudates. E and F, Posttreatment early- and late-phase fluorescein angiographic images taken at 10 months showing no evidence of leakage.
One week posttreatment, visual acuity improved to 20/200 OD. Six weeks posttreatment, a flat scar was present in the central macula with resolution of the hemorrhage and exudates. Six months posttreatment, visual acuity improved to 20/60 OD and has remained stable for more than 2 years (Figure 1D-F).
Case 2. A 15-year-old boy with a diagnosis of bilateral macular scars secondary to congenital ocular toxoplasmosis reported decreasing vision in his left eye. On examination, visual acuity was 20/100 OS. Fundus examination results revealed a macular scar with adjacent fibrosis, subretinal fluid, and hemorrhage (Figure 2A). Fluorescein angiographic images identified leakage from the CNV and blocked fluorescence corresponding to the hemorrhage (Figure 2B and C). Optical coherence tomographic images revealed increased retinal thickening and a highly reflective layer under the retina consistent with CNV (Figure 2D). The patient underwent PDT.
A, Baseline fundus photographs (OD, OS) show a macular scar with adjacent fibrosis, subretinal fluid, and the rim of hemorrhage in the left eye and a macular scar in the right eye. B and C, Baseline early- and late-phase fluorescein angiographic images show leakage from choroidal neovascularization and the rim of hypofluorescence corresponding to hemorrhage. D, Baseline vertical optical coherence tomographic scan shows increased retinal thickening and a highly reflective subretinal complex. E, Posttreatment fundus photographs taken at 6 months show a macular scar and no evidence of subretinal fluid or hemorrhage. F and G, Posttreatment early- and late-phase fluorescein angiographic images taken at 6 months show no evidence of leakage. H, Posttreatment vertical optical coherence tomographic scan taken at 6 months shows diminished retinal thickness and a persistent highly reflective subretinal complex.
One month following treatment, visual acuity improved to 20/80 OS. Fundus examination results showed a flat chorioretinal scar and complete resolution of subretinal fluid and blood. The patient's visual acuity and clinical appearance remained stable through 18 months of follow-up (Figure 2E-H).
Compared with other treatments, PDT has the theoretical advantage of selectively occluding the CNV, even in the presence of small amounts of overlying blood, without causing significant damage to the unaffected retina and choroid. Thus, PDT has the potential for vision improvement, especially in younger patients as shown in our cases. Furthermore, only a single treatment was necessary in both of these cases, unlike the 3 to 4 treatments routinely needed during the first year in patients with neovascular age-related macular degeneration.4 The decreased need for retreatment with PDT in these toxoplasmosis cases is similar to the retreatment rate observed in younger patients with postinflammatory CNV. While improvement could have occurred without PDT, these lesions were not in the process of resolving as suggested by the duration and progression of vision loss and the presence of new hemorrhages. Photodynamic therapy was most likely responsible for the observed improvements owing to the temporal relationship between treatment and the resolution of the CNV. To our knowledge, this is the second report of CNV secondary to toxoplasmosis treated with PDT5; the first report demonstrating a sustained visual acuity benefit from a single treatment with PDT, and the first successful use of PDT to treat a predominantly hemorrhagic lesion.
Correspondence: Dr Rosenfeld, Bascom Palmer Eye Institute, 900 NW 17th St, Miami, FL 33101 (firstname.lastname@example.org).
Financial Disclosure: None.
Funding/Support: This study was supported by an unrestricted grant from Research to Prevent Blindness Inc, New York, NY, and grant P30 EY14801 from the National Institutes of Health, Bethesda, Md.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 6
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.